Fermion Oy is a Finnish company that develops, manufactures, and markets active pharmaceutical ingredients (APIs) targeted at the global generic market, along with serving exclusive contracts for companies focusing on new chemical entities (NCEs). As a fully owned subsidiary of Orion Corporation and headquartered in Espoo, Finland, Fermion is part of a fully integrated contract development and manufacturing organisation (CDMO), providing comprehensive services that encompass both drug substances and drug products. Established in 1970, Fermion has been FDA inspected and approved since 1979, ensuring high quality standards in its operations.

Services include:
- Regulatory Services
- Containment
- APIs (Active Pharmaceutical Ingredients)
- Contract Development and Manufacturing (CDMO)
- cGMP Synthesis
- Contract Manufacturing (CMO)
- Manufacturing
- Custom Synthesis
- Filling
- Capsule
- Vials
- Fluid Bed Processing
- High Potency
- Clinical Trial Materials
- Controlled Substances
- Creams & Ointments
- Cytotoxic & High Potency Compounds
- Dose Form
- Non-Sterile
- Sterile
- Ethical
- Gels
- Generics
- High Containment Operations
- Injectables
- Liquids
- Nasal Delivery
- Nutraceuticals
- Oral Drug Delivery
- Orally Dispersible Tablet
- Parenterals
- Small Volume
- Semisolids
- Solid Dosage
- Solutions & Suspensions
- Sustained Release
- Tablets
- Topicals
- Animal Health
- Packaging
- Anti-Counterfeiting
- Blister
- Clinical Trials
- Tubes
- Ampule
- Sustained Release Delivery Systems
- Tablet Coating

Fermion Oy stands out in the pharmaceutical industry for its custom development and GMP manufacturing of APIs and advanced intermediates, effectively improving time to market while reducing costs. For more information, please visit fermion.fi.